“Lab innovation is key to optimizing COVID-19 capacity,” said Steve Rusckowski, president, CEO and president of Quest Diagnostics. “We appreciate the FDA’s cooperation in bringing this strategy to several of our laboratories in the United States.
With the new U.S. FDA, five of the company’s laboratories in the United States can now use this new RNA extraction approach, adding samples from organizations. These labs are well geographically to meet the increased demand for testing in states where the virus has increased. The laboratories are in San Juan Capistrano and Valencia, California; Lewisville, Texas; Lenexa, Kansas; Chantilly, Virginia; and Marlborough, Massachusetts.